发布时间 : 星期一 文章2009年版版英国再障诊疗指南解读（血液学组谢晓恬教授提供）更新完毕开始阅读c02cc4610166f5335a8102d276a20029bc646313
选文献资料范围广，数据详实可靠，因此将在今后相当长的时间内，具有重要的参考价值。正如Camitta于1975年推荐的再障诊断标准虽已有近40年历史，但仍沿用至今，仍被作为目前国际上公认的标准[2]。虽然《09版指南》主要针对于成人再障，但基本能满足儿童再障的临床技术参照要求，并推荐可适当参考有关儿童再障的专题文献[20]。此外，由于目前对于再障发病机制的认识仍欠全面，致使研究进展相对缓慢，《09版指南》的某些方面可能并不太非常符合我国等亚裔人群再障患者。因此，希望通过共同努力，使我国儿童再障领域在受重视程度、研究投入、受众范围和疗效水平等方面，缩短与儿童白血病诊治研究间的差距，并与国际接轨。相信随着国内外持续探索、研究和总结，获得性再障的治疗技术与疗效水平会不断得到提高。 参考文献
[1] Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia[J]. Br J Haematol, 2009, 147(1): 43-70. [2] Camitta BM, Rappeport JM, Parkman R,et al. Selection of patients for bone marrow transplantation in severe aplastic anemia[J]．Blood,1975,45(3):355-363.
[3] Bacigalupo A, Hows J, Gluckman E,et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party[J]. Br J Haematol,1988,70(2):177-182.
[4] Young NS，Bacigalupo A，Marsh JCW. Aplastic Anemia: Pathophysiology and Treatment[J]. Biol Blood Marrow Transplant，2010，16：S119-125. [5] Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia[J]. Blood, 2006, 108(8): 2509-2519.
[6] Peinemann F, GrouvenU, Kr?ger N, et al.Unrelated donor stem cell transplantation in acquired severe aplastic anemia：a systematic review. Haematologica，2009，94(12)：1－11.
[7] Scheinberg P,Nunez O,Young NS. Retreatment with rabbit anti-thymocyte
globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol, 2006，133：622–627.
[8] Camitta BM. What is the definition of cure for aplastic anemia?[J]. Acta Haematol, 2000, 103(1): 16-18.
[9] Xiaotian Xie，Wei Shi，Xiaoxun Zhou，et al. Comparison of rabbit antithymocyte globulin and Jurkat cell-reactive anti-t lymphocyte globulin as a first-line treatment for children with aplastic anemia. Exp Hematol, Dol: 10.1016/j.exphem.2014.02.003.
[10] 谢晓恬，赵惠君，覃大卫.抗胸腺细胞球蛋白治疗儿童再生障碍性贫血药代动力学研究. 中华实用儿科临床杂志，2013，28（15）：1134－1137.
[11] Young NS, Scheinberg P，Calado RT. Aplastic anemia. Curr Opin Hematol，2008, 15：162–168.
[12] Fuehrer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for aplastic anaemia in children: a more severe disease predicts better survival. Blood，2005，106：2102-2104.
[13] Jaime-Pérez JC，Colunga-Pedraza PR，Gómez-Ramírez CD，et al. Danazol as first-line therapy for aplastic anemia. Ann Hematol，2011，90：523–527. [14] Calado RT，Young NS. Telomere maintenance and human bone marrow failure。Blood ，2008，111：4446-4455.
[15] PongtanakulB，Das PK，Karen Charpentier，et al.Outcome of Children With Aplastic Anemia Treated With Immunosuppressive Therapy. Pediatr Blood Cancer，2008，50：52–57
[16] Locasciulli A，Oneto R，Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation. Haematologica， 2007，92：11－18
[17] Zheng Y, Liu Y, Chu Y，et al. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): A prospective comparison of four different
regimens. Exp Hematol，2006，34：826–831
[18] Gurion R，Gafter-Gvili A，Paul M，et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy -systematic review and meta-analysis. Haematologica，2009，94：712-719. [19] Afable MG，Shaik M，Sugimoto Y，et al.Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica，2011，96(9):1269-1275 [20] Davies1 JK，Guinan EC. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol,2007，136：549–564